Buy Daivonex® ointment 50 mcg/g, 30 g
  • Buy Daivonex® ointment 50 mcg/g, 30 g

Daivonex® [Calcipotriol]

Leo Pharmaceutical
547 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$68.06
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Pharmacodynamics

Drug for the treatment of psoriasis.

Calcipotriol is a synthetic analogue of the active metabolite of vitamin D, stimulates the morphological differentiation and suppresses the proliferation of keratinocytes, which underlies its therapeutic effect in psoriasis.

Calcipotriol is a potent inhibitor of T-lymphocyte activation caused by interleukin I.

The effect of calcipotriol on calcium metabolism is 100 times weaker than vitamin D3.

Pharmacokinetics

The transdermal absorption of calcipotriol is, depending on the dose used, from 1% to 5%. Calcipotriol undergoes rapid biotransformation in the liver with the formation of pharmacologically inactive metabolites. T 1/2 very short.

Indications

Vulgar psoriasis, incl. chronic psoriasis of the scalp.

Composition

1 g of ointment for external use contains:

Active substance: Calcipotriol 50 mcg.

Excipients: disodium edetate, sodium hydrogen phosphate, α-tocopherol, liquid paraffin, polyethylene glycol stearate, propylene glycol, white paraffin, water.

No customer reviews for the moment.

Write your review

Write your review

Daivonex® [Calcipotriol]

Dosage and Administration

Ointment is applied with a thin layer to the affected skin 2 times / day. The therapeutic effect is usually observed after 1-2 weeks from the start of treatment. The duration of treatment is no more than 6-8 weeks.

  • For adults: the maximum daily dose is 15 g, the maximum dose per week is not more than 100 g
  • For children over the age of 12: the maximum dose per week is 75 g.
  • For children aged 6 to 12 years: the maximum dose per week is not more than 50 g.

Adverse reactions

Dermatological reactions: local irritation of the skin, erythema and itching of the skin are possible; rarely - dermatitis, exacerbation of psoriasis; in some cases - hyperpigmentation, photosensitivity.

Metabolism: hypercalciuria, hypercalcemia.

Contraindications

With caution should use the drug for: hypercalcemia, hypercalciuria, hypervitaminosis D, nephrolithiasis. In children due to lack of experience of use. In patients older than 65 years.

Drug interactions

Dayvoneks should not be used simultaneously with topical preparations containing salicylic acid.

Pregnancy and Lactation

The safety of the drug during pregnancy and lactation has not been established.

It is not known whether calcipotriol is excreted in breast milk.

Special instructions

It is not recommended to apply ointment to the skin.

To avoid contact of the drug with the skin of the face, hands should be thoroughly washed after each use of the ointment.

Hypercalcemia develops when the maximum dose of calcipotriol for the week is exceeded. With the abolition of the drug, the concentration of calcium in the blood quickly normalizes.

Dayvonex treatment can be combined with PUVA therapy.

Impact on the ability to drive vehicles and other mechanisms that require high concentration of attention

Dayvoneks does not affect the ability to drive vehicles and control mechanisms.

Overdosage

Symptoms: with the use of the drug in doses exceeding the recommended, it is possible to increase the concentration of calcium in the blood.

Treatment: drug withdrawal.

  • Brand name: Dayvoneks
  • Active ingredient: Calcipotriol
  • Dosage form: Ointment for external use.
  • Manufacturer: Leo Pharmaceutical
  • Country of Origin: Denmark

Studies and clinical trials of Calcipotriol (Click to expand)

  1. LC separation of calcipotriol from its photodegradation products and protection possibilities using adjuvants
  2. Calcipotriol for erythema annulare centrifugum
  3. Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparative flow cytometric study
  4. Safety and efficacy of calcipotriol ointment (Dovonex®) in treating children with psoriasis vulgaris
  5. Effects of calcipotriol on stratum corneum barrier function, hydration and cell renewal in humans
  6. Successful treatment for acrodermatitis continua of Hallopeau using topical calcipotriol
  7. Topical calcipotriol in the treatment of intertriginous psoriasis
  8. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study
  9. The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis
  10. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study
  11. The calcipotriol dose–irritation relationship: 48 hour occlusive testing in healthy volunteers using Finn Chambers®
  12. Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients
  13. Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol
  14. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy
  15. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid
  16. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells
  17. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis
  18. Re-epithelialization rate and protein expression in the suction-induced wound model: comparison between intact blisters, open wounds and calcipotriol-pretreated open wounds
  19. Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema
  20. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis
  21. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial
  22. Calcipotriol toxicity in dogs

8 other products in the same category:

arrow_upward